Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Pat Price, MA, MD, FRCR, FRCP
Advertisement
Articles by Pat Price, MA, MD, FRCR, FRCP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC
2
Sevabertinib Monotherapy Elicits Durable Responses in HER2-Mutant NSCLC
3
Zongertinib Maintains Efficacy Benefit in First-line HER2-Mutated NSCLC
4
Episode 16: Anticipated ESMO 2025 Data That May Change GU Oncology
5
